{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T22:21:59Z","timestamp":1792707719466,"version":"4.5.0"},"reference-count":40,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2022,9,7]],"date-time":"2022-09-07T00:00:00Z","timestamp":1662508800000},"content-version":"unspecified","delay-in-days":6,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2022,8,1]]},"published-print":{"date-parts":[[2022,9]]},"abstract":"\n Objective<\/jats:title>\n Post hoc analysis of pooled data from nine randomised controlled trials to assess the effect of tofacitinib (oral Janus kinase inhibitor for treatment of rheumatoid arthritis (RA) and psoriatic arthritis (PsA)) on residual pain in patients with RA or PsA with abrogated inflammation.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n Patients who received \u22651\u2009dose of tofacitinib 5 mg twice daily, adalimumab or placebo with\/without background conventional synthetic disease-modifying antirheumatic drugs and had abrogated inflammation (swollen joint count (SJC)=0 and C reactive protein (CRP)<6 mg\/L) after 3 months\u2019 therapy were included. Assessments included Patient\u2019s Assessment of Arthritis Pain at month 3 (Visual Analogue Scale [VAS] 0\u2013100 mm). Scores were summarised descriptively; treatment comparisons assessed by Bayesian network meta-analyses (BNMA).<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n From the total population with RA\/PsA, 14.9% (382 of 2568), 17.1% (118 of 691) and 5.5% (50 of 909) of patients receiving tofacitinib, adalimumab and placebo, respectively, had abrogated inflammation after 3 months\u2019 therapy. Patients with RA\/PsA with abrogated inflammation receiving tofacitinib\/adalimumab had higher baseline CRP versus placebo; patients with RA receiving tofacitinib\/adalimumab had lower SJC and longer disease duration versus placebo. Median residual pain (VAS) at month 3 was 17.0, 19.0 and 33.5 in patients with RA treated with tofacitinib, adalimumab or placebo, and 24.0, 21.0 and 27.0 in patients with PsA, respectively. Residual pain reductions with tofacitinib\/adalimumab versus placebo were less prominent in patients with PsA versus patients with RA, with no significant differences between tofacitinib\/adalimumab, per BNMA.<\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n Patients with RA\/PsA with abrogated inflammation receiving tofacitinib\/adalimumab had greater residual pain reduction versus placebo at month 3. Results were similar between tofacitinib and adalimumab.<\/jats:p>\n <\/jats:sec>\n \n Trial registration number<\/jats:title>\n ClinicalTrials.gov registry (NCT00960440<\/jats:ext-link>; NCT00847613<\/jats:ext-link>; NCT00814307<\/jats:ext-link>; NCT00856544<\/jats:ext-link>; NCT00853385<\/jats:ext-link>; NCT01039688<\/jats:ext-link>; NCT02187055<\/jats:ext-link>; NCT01877668<\/jats:ext-link>; NCT01882439<\/jats:ext-link>).<\/jats:p>\n <\/jats:sec>","DOI":"10.1136\/rmdopen-2022-002478","type":"journal-article","created":{"date-parts":[[2022,9,7]],"date-time":"2022-09-07T10:58:51Z","timestamp":1662548331000},"page":"e002478","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":25,"title":["The effect of tofacitinib on residual pain in patients with rheumatoid arthritis and psoriatic arthritis"],"prefix":"10.1136","volume":"8","clinical-trial-number":[{"clinical-trial-number":"nct00960440","registry":"10.18810\/clinical-trials-gov","type":"results"},{"clinical-trial-number":"nct00847613","registry":"10.18810\/clinical-trials-gov","type":"results"},{"clinical-trial-number":"nct00814307","registry":"10.18810\/clinical-trials-gov","type":"results"},{"clinical-trial-number":"nct00856544","registry":"10.18810\/clinical-trials-gov","type":"results"},{"clinical-trial-number":"nct00853385","registry":"10.18810\/clinical-trials-gov","type":"results"},{"clinical-trial-number":"nct01039688","registry":"10.18810\/clinical-trials-gov","type":"results"},{"clinical-trial-number":"nct02187055","registry":"10.18810\/clinical-trials-gov","type":"results"},{"clinical-trial-number":"nct01877668","registry":"10.18810\/clinical-trials-gov","type":"results"},{"clinical-trial-number":"nct01882439","registry":"10.18810\/clinical-trials-gov","type":"results"},{"clinical-trial-number":"nct00960440","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00847613","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00814307","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00856544","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00853385","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01039688","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02187055","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01877668","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01882439","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3009-6229","authenticated-orcid":false,"given":"Maxime","family":"Dougados","sequence":"first","affiliation":[{"name":"Department of Rheumatology, H\u00f4pital Cochin, Universit\u00e9 de Paris, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7766-6167","authenticated-orcid":false,"given":"Peter C","family":"Taylor","sequence":"additional","affiliation":[{"name":"Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"Clifton O","family":"Bingham","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Johns Hopkins University, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara","family":"Fallon","sequence":"additional","affiliation":[{"name":"Global Medical Affairs, Rheumatology, Pfizer Inc, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Brault","sequence":"additional","affiliation":[{"name":"Pfizer Inc, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satrajit","family":"Roychoudhury","sequence":"additional","affiliation":[{"name":"Pfizer Inc, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisy","family":"Wang","sequence":"additional","affiliation":[{"name":"Global Product Development, Pfizer Inc, Groton, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meriem","family":"Kessouri","sequence":"additional","affiliation":[{"name":"Pfizer Inc, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2022,9,7]]},"reference":[{"key":"2025090312452306000_8.2.e002478.1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(16)30173-8. PubMed PMID: 27156434."},{"key":"2025090312452306000_8.2.e002478.2","doi-asserted-by":"crossref","first-page":"ii14","DOI":"10.1136\/ard.2004.032482","article-title":"Psoriatic arthritis: epidemiology, clinical features, course, and outcome","volume":"64 Suppl 2","author":"Gladman","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"2025090312452306000_8.2.e002478.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1505557"},{"key":"2025090312452306000_8.2.e002478.4","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-205207"},{"key":"2025090312452306000_8.2.e002478.5","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20005"},{"key":"2025090312452306000_8.2.e002478.6","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20151"},{"key":"2025090312452306000_8.2.e002478.7","doi-asserted-by":"crossref","DOI":"10.1186\/1476-9255-1-1","article-title":"The Journal of inflammation","volume":"1","author":"Punchard","year":"2004","journal-title":"J Inflamm"},{"key":"2025090312452306000_8.2.e002478.8","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2014.64"},{"key":"2025090312452306000_8.2.e002478.9","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1002\/art.39698","article-title":"Quantification and impact of secondary osteoarthritis in patients with anti-citrullinated protein antibody-positive rheumatoid arthritis","volume":"68","author":"Figueiredo","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2025090312452306000_8.2.e002478.10","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1002\/acr.24369","article-title":"Systematic literature review of residual symptoms and an unmet need in patients with rheumatoid arthritis","volume":"73","author":"Michaud","year":"2021","journal-title":"Arthritis Care Res"},{"key":"2025090312452306000_8.2.e002478.11","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s00296-018-4201-3","article-title":"Residual symptoms and disease burden among patients with psoriatic arthritis: is a new disease activity index required?","volume":"39","author":"Kilic","year":"2019","journal-title":"Rheumatol Int"},{"key":"2025090312452306000_8.2.e002478.12","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1080\/14397595.2017.1416940","article-title":"Residual symptoms and disease burden among patients with rheumatoid arthritis in remission or low disease activity: a systematic literature review","volume":"28","author":"Ishida","year":"2018","journal-title":"Mod Rheumatol"},{"key":"2025090312452306000_8.2.e002478.13","doi-asserted-by":"crossref","DOI":"10.1186\/s12974-016-0556-0","article-title":"Neuron-immune mechanisms contribute to pain in early stages of arthritis","volume":"13","author":"Nieto","year":"2016","journal-title":"J Neuroinflammation"},{"key":"2025090312452306000_8.2.e002478.14","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1097\/BOR.0000000000000388","article-title":"Fibromyalgia, a missed comorbidity in spondyloarthritis: prevalence and impact on assessment and treatment","volume":"29","author":"Mease","year":"2017","journal-title":"Curr Opin Rheumatol"},{"key":"2025090312452306000_8.2.e002478.15","doi-asserted-by":"publisher","DOI":"10.1186\/ar2842"},{"key":"2025090312452306000_8.2.e002478.16","doi-asserted-by":"publisher","DOI":"10.1002\/art.23063"},{"key":"2025090312452306000_8.2.e002478.17","doi-asserted-by":"publisher","DOI":"10.1002\/art.22282"},{"key":"2025090312452306000_8.2.e002478.18","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/1756-185X.13160","article-title":"Association between serum vitamin D levels and neuropathic pain in rheumatoid arthritis patients: a cross-sectional study","volume":"21","author":"Yesil","year":"2018","journal-title":"Int J Rheum Dis"},{"key":"2025090312452306000_8.2.e002478.19","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61424-X"},{"key":"2025090312452306000_8.2.e002478.20","first-page":"848","article-title":"Tofacitinib in combination with methotrexate in patients with rheumatoid arthritis: patient-reported outcomes from the 24-month phase 3 oral scan study","volume":"38","author":"Strand","year":"2020","journal-title":"Clin Exp Rheumatol"},{"key":"2025090312452306000_8.2.e002478.21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1109071"},{"key":"2025090312452306000_8.2.e002478.22","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-159-4-201308200-00006"},{"key":"2025090312452306000_8.2.e002478.23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1112072"},{"key":"2025090312452306000_8.2.e002478.24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1310476"},{"key":"2025090312452306000_8.2.e002478.25","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31618-5"},{"key":"2025090312452306000_8.2.e002478.26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1615975"},{"key":"2025090312452306000_8.2.e002478.27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1615977"},{"key":"2025090312452306000_8.2.e002478.28","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2019-001042"},{"key":"2025090312452306000_8.2.e002478.29","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2022-eular.58","article-title":"OP0052 The effect of tofacitinib on residual pain in patient with rheumatoid arthritis and psoriatic arthritis with complete control of inflammation [abstract]","volume":"81","author":"Dougados","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"2025090312452306000_8.2.e002478.30","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1002\/acr.23994","article-title":"Association of pain centralization and patient-reported pain in active rheumatoid arthritis","volume":"72","author":"Heisler","year":"2020","journal-title":"Arthritis Care Res"},{"key":"2025090312452306000_8.2.e002478.31","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2021-001609"},{"key":"2025090312452306000_8.2.e002478.32","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.semarthrit.2020.10.008","article-title":"The Jak\/STAT pathway: a focus on pain in rheumatoid arthritis","volume":"51","author":"Simon","year":"2021","journal-title":"Semin Arthritis Rheum"},{"key":"2025090312452306000_8.2.e002478.33","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.2008.05566.x"},{"key":"2025090312452306000_8.2.e002478.34","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.joca.2020.01.012","article-title":"Targeting GM-CSF for collagenase-induced osteoarthritis pain and disease in mice","volume":"28","author":"Lee","year":"2020","journal-title":"Osteoarthritis Cartilage"},{"key":"2025090312452306000_8.2.e002478.35","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1011774108"},{"key":"2025090312452306000_8.2.e002478.36","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-eular.1052"},{"key":"2025090312452306000_8.2.e002478.37","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0180014","article-title":"Pain and pain mechanisms in patients with inflammatory arthritis: a Danish nationwide cross-sectional DANBIO registry survey","volume":"12","author":"Rifbjerg-Madsen","year":"2017","journal-title":"PLoS One"},{"key":"2025090312452306000_8.2.e002478.38","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2018-000656"},{"key":"2025090312452306000_8.2.e002478.39","doi-asserted-by":"crossref","first-page":"831","DOI":"10.3390\/jcm8060831","article-title":"Achieving pain control in rheumatoid arthritis with baricitinib or adalimumab plus methotrexate: results from the RA-BEAM trial","volume":"8","author":"Taylor","year":"2019","journal-title":"J Clin Med"},{"key":"2025090312452306000_8.2.e002478.40","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2019-001131"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2022-002478","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T19:45:27Z","timestamp":1756928727000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2022-002478"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":40,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,9,7]]},"published-print":{"date-parts":[[2022,9]]}},"alternative-id":["10.1136\/rmdopen-2022-002478"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2022-002478","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9]]}}}